Hikma Recalls Ramipril Capsules Due to Process Impurity
Hikma Pharmaceuticals is recalling specific lots of Ramipril 10 mg capsules because they failed impurity specifications for dicyclohexylurea.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically corresponds to a Moderate severity score (2) in the absence of reported hospitalizations or significant injuries, as the hazard is a process impurity failure without reported adverse health consequences.
Plain-English summary
Hikma Pharmaceuticals USA INC. is recalling Ramipril Capsules USP, 10 mg, manufactured for Exelan Pharmaceuticals, Inc. The affected products are packaged in bottles of 100 capsules (NDC 76282-673-01) and 500 capsules (NDC 76282-673-05). The recall involves Lot AC5470A and Lot AC5470B, both with an expiration date of July 2027. A total of 25,970 bottles of the 100-capsule size and 2,384 bottles of the 500-capsule size are affected.
The recall was initiated because the product failed impurities/degradation specifications. Specifically, an out-of-specification (OOS) result was obtained for a process impurity known as dicyclohexylurea (DCU). The FDA has classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The affected products were distributed nationwide within the United States. Consumers and healthcare providers should check their inventory for the specific NDC numbers, lot numbers, and expiration dates listed above. If the product matches the recalled description, it should be returned to the pharmacy or point of purchase for a refund or replacement.
The recalled product
- Product
- RAMIPRIL (RAMIPRIL)
- Brand
- RAMIPRIL
- Manufacturer
- Hikma Pharmaceuticals USA INC.
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- a) Lot #: AC5470A
- Exp. Date July 2027 b) Lot #: AC5470B
- Exp. Date July 2027
UPCs (3)
- 0376282670010
- 0376282672014
- 0376282673011
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RAMIPRIL
- HighFDA recalls Ramipril 2.5 mg capsules for manufacturing control deviations
FDA (Drugs) · 2024-11-27
- HighRamipril Capsule Medication Recalled Over Unapproved Vendor Manufacturing Deviations
FDA (Drugs) · 2024-11-27
- HighPrescription Drug Recall: Ramipril Capsules from Unapproved Supplier
FDA (Drugs) · 2024-11-27
Same manufacturer · Hikma Pharmaceuticals USA INC.
See all →- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28
- HighMorphine Sulfate Ampuls Recalled for Expired Filters in Cartons
FDA (Drugs) · 2024-03-27
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
Same hazard · impurity
See all →- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateDuloxetine Delayed-Release Capsules 20 mg Recalled for Impurity
FDA (Drugs) · 2026-05-13